Since raising a mind-boggling $1 billion in 2024, AI-driven Xaira Therapeutics has remained largely silent on where that money is being put to work. Last week, the company’s Chief Operating Officer, Jeff Jonker, opened up to Fierce Biotech, divulging details about the secretive biotech’s efforts in inflammatory and immunological science.


